Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II/III Randomized Clinical Trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence: PURITY Study

NCT06037980 is registered in ClinicalTrials.gov with Gruppo Oncologico del Nord-Ovest as lead sponsor.

NCT NCT06037980
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06037980 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II/III Randomized Clinical Trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence: PURITY Study
Lead sponsor
Gruppo Oncologico del Nord-Ovest
Phase
Phase 2/3
Overall status
Recruiting
Start date
November 7, 2023
Completion date
January 31, 2029
Enrollment
300 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

biliary tract cancer, cholangiocarcinoma